Management of Refractory Typical GERD Symptoms

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2016 Apr 15

PMID 27075264

Citations 29

Authors

Emidio Scarpellini

Daphne Ang

Ans Pauwels

Adriano De Santis

Tim Vanuytsel

Jan Tack

Affiliations

Soon will be listed here.

Abstract

The management of patients with refractory GERD (rGERD) is a major clinical challenge for gastroenterologists. In up to 30% of patients with typical GERD symptoms (heartburn and/or regurgitation), acid-suppressive therapy does not provide clinical benefit. In this Review, we discuss the current management algorithm for GERD and the features and management of patients who do not respond to treatment (such as those individuals with an incorrect diagnosis of GERD, inadequate PPI intake, persisting acid reflux and persisting weakly acidic reflux). Symptom response to existing surgical techniques, novel antireflux procedures, and the value of add-on medical therapies (including prokinetics and reflux inhibitors) for rGERD symptoms are discussed. Pharmaceutical agents targeting oesophageal sensitivity, a condition that can contribute to symptom generation in rGERD, are also discussed. Finally, on the basis of available published data and our expert opinion, we present an outline of a current, usable algorithm for management of patients with rGERD that considers the timing and diagnostic use of pH-impedance monitoring on or off PPI, additional diagnostic tests, the clinical use of baclofen and the use of add-on neuromodulators (tricyclic agents and selective serotonin reuptake inhibitors).

Citing Articles

Global Transcriptomic Analysis of Topical Sodium Alginate Protection against Peptic Damage in an In Vitro Model of Treatment-Resistant Gastroesophageal Reflux Disease.

Ergun P, Samuels T, Mathison A, Plehhova K, Coyle C, Horvath L Int J Mol Sci. 2024; 25(19).

PMID: 39409043 PMC: 11605242. DOI: 10.3390/ijms251910714.

Efficacy of Shugan Hewei formula combined with rabeprazole in refractory gastroesophageal reflux disease: randomized, double-blind, placebo-controlled trial.

Zhang X, Wang Z, Xu T, Wei L, Liu F, Liu C Eur J Med Res. 2024; 29(1):466.

PMID: 39300586 PMC: 11412052. DOI: 10.1186/s40001-024-02030-z.

A scientometrics analysis and visualization of refractory gastroesophageal reflux disease.

Zhang N, Han M, Zheng Q, Zhang M, Zhi W, Li J Front Pharmacol. 2024; 15:1393526.

PMID: 39139634 PMC: 11319146. DOI: 10.3389/fphar.2024.1393526.

Laparoscopic floppy Nissen fundoplication with valve calibration: a safe and efficient procedure.

de Ponthaud C, Voron T, Paye F Surg Today. 2024; 54(9):1041-1050.

PMID: 38589734 DOI: 10.1007/s00595-024-02817-x.

Latin American consensus on diagnosis of gastroesophageal reflux disease.

Olmos J, Pandolfino J, Piskorz M, Zamora N, Valdovinos Diaz M, Remes Troche J Neurogastroenterol Motil. 2024; 36(3):e14735.

PMID: 38225792 PMC: 11720354. DOI: 10.1111/nmo.14735.

References

Louie B, Farivar A, Shultz D, Brennan C, Vallieres E, Aye R . Short-term outcomes using magnetic sphincter augmentation versus Nissen fundoplication for medically resistant gastroesophageal reflux disease. Ann Thorac Surg. 2014; 98(2):498-504. DOI: 10.1016/j.athoracsur.2014.04.074. View

Herregods T, Troelstra M, Weijenborg P, Bredenoord A, Smout A . Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015; 27(9):1267-73. DOI: 10.1111/nmo.12620. View

Boeckxstaens G, Beaumont H, Mertens V, Denison H, Ruth M, Adler J . Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology. 2010; 139(2):409-17. DOI: 10.1053/j.gastro.2010.04.051. View

Sifrim D, Zerbib F . Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012; 61(9):1340-54. DOI: 10.1136/gutjnl-2011-301897. View

Katzka D, Paoletti V, Leite L, Castell D . Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol. 1996; 91(10):2110-3. View

Orr W, Goodrich S, Wright S, Shepherd K, Mellow M . The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. Neurogastroenterol Motil. 2012; 24(6):553-9, e253. DOI: 10.1111/j.1365-2982.2012.01900.x. View

Hunter J, Kahrilas P, Bell R, Wilson E, Trad K, Dolan J . Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. Gastroenterology. 2014; 148(2):324-333.e5. DOI: 10.1053/j.gastro.2014.10.009. View

Vakil N, Huff F, Cundy K . Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. Aliment Pharmacol Ther. 2013; 38(2):107-17. DOI: 10.1111/apt.12363. View

Yamashita H, Ashida K, Fukuchi T, Nagatani Y, Koga H, Senda K . Combined pH-impedance monitoring and high-resolution manometry of Japanese patients treated with proton-pump inhibitors for persistent symptoms of non-erosive reflux disease. J Smooth Muscle Res. 2013; 48(5-6):125-35. DOI: 10.1540/jsmr.48.125. View

10.

Keywood C, Wakefield M, Tack J . A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut. 2009; 58(9):1192-9. PMC: 2719084. DOI: 10.1136/gut.2008.162040. View

11.

Shaheen N, Adler J, Dedrie S, Johnson D, Malfertheiner P, Miner P . Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy. Aliment Pharmacol Ther. 2015; 41(7):649-61. PMC: 5024018. DOI: 10.1111/apt.13115. View

12.

Viazis N, Keyoglou A, Kanellopoulos A, Karamanolis G, Vlachogiannakos J, Triantafyllou K . Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2011; 107(11):1662-7. DOI: 10.1038/ajg.2011.179. View

13.

Lim H, Kim J, Youn Y, Lee E, Lee B, Park H . Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study. J Neurogastroenterol Motil. 2013; 19(4):495-502. PMC: 3816184. DOI: 10.5056/jnm.2013.19.4.495. View

14.

Gorelick A, Koshy S, Hooper F, Bennett T, Chey W, Hasler W . Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol. 1998; 275(3):G460-6. DOI: 10.1152/ajpgi.1998.275.3.G460. View

15.

Holtmann G, Talley N, Liebregts T, Adam B, Parow C . A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006; 354(8):832-40. DOI: 10.1056/NEJMoa052639. View

16.

Campos G, Peters J, DeMeester T, Oberg S, Crookes P, Tan S . Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999; 3(3):292-300. DOI: 10.1016/s1091-255x(99)80071-7. View

17.

Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V . A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995; 333(17):1106-10. DOI: 10.1056/NEJM199510263331703. View

18.

Hayden J, Jamieson G . Optimization of outcome after laparoscopic antireflux surgery. ANZ J Surg. 2006; 76(4):258-63. DOI: 10.1111/j.1445-2197.2006.03691.x. View

19.

Trad K, Barnes W, Simoni G, Shughoury A, Mavrelis P, Raza M . Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial. Surg Innov. 2014; 22(1):26-40. PMC: 4361451. DOI: 10.1177/1553350614526788. View

20.

Perry K, Banerjee A, Melvin W . Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech. 2012; 22(4):283-8. DOI: 10.1097/SLE.0b013e3182582e92. View